Inhalation Anesthetics Market Size, Share, By Product Type (Sevoflurane, Desflurane, Isoflurane, and Others), Application (Induction and Maintenance), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Region - Trends, Analysis, and Forecast till 2035

• By 2035, the inhalation anesthetics market size is projected to grow at a valuation of USD 4.0 Billion.
• The inhalation anesthetics industry was calculated at USD 2.2 Billion by 2024.
• The target market is developing at a CAGR of 5.8%.

Inhalation anesthetics are drugs that are given by breathing; for example, isoflurane, sevoflurane, and nitrous oxide. These drugs cause a patient to inhale a gaseous substance that enters the lungs and enters the bloodstream, causing it to become unconscious and pain-free. The rising prevalence of chronic diseases, such as cancer, cardiovascular disease, and respiratory disease, increase in surgeries globally, due to an increase in emergency situations, accidents, and chronic diseases, the development of new anesthetic drug delivery systems, and government-support provided for use of inhalation anesthetics is stimulating the inhalation anesthetics market growth.

Additionally, inhalation anesthetics provide rapid onset and recovery, easy control of anesthetic depth, athe bility to quickly adjust the level of anesthesia, and minimal systemic side effects, thus contributing to market augmentation.

Influence of AI on the Inhalation Anesthetics Market:

Artificial intelligence (AI) has the potential to greatly influence the way inhalation anesthetics are administered by facilitating more accurate monitoring of a patient's anesthetic depth, customized dosage adjustments, real-time problem detection, and possible anesthetic delivery optimization, all of which will ultimately improve patient safety and expedite operating room procedures.

Key Drivers of Target Market:

Market is Augmenting Owing to the Rise in Surgeries Globally

Every surgery needs anesthesia and many of these surgeries use inhalation anesthetics. This means, as the number of surgeries rises, the demand for these anesthetic agents to manage patient pain during operations also rises. As a result, the market for inhalation anesthetics is directly driven by an increase in global surgical procedures.

• For instance, in June 2024, The International Society of Aesthetic Plastic Surgery (ISAPS) released the results of its annual Global Survey on Aesthetic/Cosmetic Procedures at the ISAPS World Congress in Cartagena, showing a higher increase of 5.5% in surgical procedures, with more than 15.8 million procedures performed by plastic surgeons and 19.1 non-surgical procedures. Over the last four years, the overall increase was 40%.

Restraints:

Harmful Environmental Impact of Inhalation Anesthetic is Hindering the Market Growth

Inhalation anesthetics can contribute to greenhouse gas emissions and have negative environmental consequences as it is released into the atmosphere. Healthcare professionals can face health hazards from prolonged exposure. Other factors that limit its utilization include high prices and restricted accessibility in some areas. Operations are made more difficult by stringent handling and storage regulations.

• Counterbalance Statements: Emissions and exposure concerns can be decreased by implementing gas scavenging systems and low-flow anesthetic procedures. To further reduce the impact on the environment, research on eco-friendly anesthetic substitutes should be encouraged.

Opportunities:

Incorporating Advanced Technologies with Inhalation Anesthetics to Fuel Market Growth in the Future

By enabling more accurate drug delivery, improved patient monitoring, decreased complications, quicker recovery times, enhanced training capabilities, and optimized resource utilization, integrating advanced technologies, such as smart technologies and digital monitoring systems with inhalation anesthetics can propel market growth. In the end, this will increase the use of inhalation anesthesia in a variety of surgical procedures and improve patient outcomes, making it a more appealing choice for healthcare providers.

• For instance, in April 2024, GE Healthcare announced the FDA pre-market approval (PMA) for its End-tidal (Et) Control software for general anesthesia delivery on its Aisys CS2 Anesthesia Delivery System, which was a digital monitoring system. GE Healthcare was the only manufacturer approved to offer general anesthesia delivery with end-tidal concentration control in the U.S.

The inhalation anesthetics market is segmented into product type, application, end-user, and region.

Product Type

According to product type, the market is sub-segmented into sevoflurane, desflurane, isoflurane, and others. The sevolflurane segment is expected to hold the largest inhalation anesthetics market share during the forecast period. The segment’s expansion is driven by the favorable properties of sevolflurane, including a rapid onset, quick recovery time, minimal side effects, pleasant odor, and low airway irritation, making it the preferred choice for a wide range of surgical procedures.

• For instance, in March 2025, OhioHealth had done away with the inhaled anesthetic gas desflurane in exchange for sevoflurane due to the former’s harmful effect on the environment. This shift pushed OhioHealth closer toward its climate and sustainability goals and the company was in line with the standards of other networks, as desflurane is the inhaled anesthetic that is the most potent greenhouse gas with the most global warming potential.

Application

Under application, the market is bifurcated into induction and maintenance. The maintenance segment is attributed to dominate the market owing to its high use for sustaining anesthesia throughout a surgical procedure, making it more prolonged and consistent as compared to the initial induction phase.

End-User

On the basis of end-user, the market is trifurcated into hospitals, ambulatory surgical centers, and others. The ambulatory surgical centers is projected to influence the market as it prioritizes quick recovery times and cost-effectiveness, which aligns perfectly with the benefits of inhalation anesthetics allowing patients to go home shortly after surgery without requiring extended stays.

Region

Geographically, the market is classified into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America: North America is leading the inhalation anesthetics market with an estimated share of 52.9%. This is due to its high volume of surgical procedures performed, a well-developed healthcare infrastructure, a growing elderly population, advanced anesthetic technologies, and a strict regulatory oversight that ensures patient safety.

• For instance, in January 2022, Dechra Pharmaceuticals had acquired Isoflurane USP Inhalant Anesthetic and Sevoflurane USP Inhalant Anesthetic from Halocarbon Life Sciences. The 2 inhalation anesthesia solutions or anesthetics were used in both human and animal medicine. The company also planned to launch veterinary branded Isoflurane and Sevoflurane products as well.

Europe: This is the region with the fastest growing market, during the forecast period. This is due to this region’s, rising rapidly aging population, high volume of surgeries performed, well-developed healthcare infrastructure, government initiatives promoting minimally invasive surgeries, and a significant prevalence of chronic diseases.

• For instance, in March 2023, NHS Scotland and NHS England were the first health systems in the world to announce a phase-out of desflurane, an anaesthetic gas with a global warming potential 2,500 times greater than carbon dioxide, this leading the U.K. healthcare. NHS Scotland announced an immediate ban on desflurane use, while NHS England was committed to phasing it out.

Inhalation Anesthetics Market Report Scope:

Segmentation:

By Product:

• Sevoflurane
• Desflurane
• Isoflurane
• Others

By Application:

• Induction
• Maintenance

By End User:

• Hospitals
• Ambulatory Surgical Centers
• Others

By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • Indonesia
  • Malaysia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of the Middle East & Africa

The companies operating in the inhalation anesthetics market are Baxter, AbbVie, Fresenius Kabi Canada Ltd., Halocarbon, LLC, Piramal Critical Care, and others. The key players are adopting strategies such as developing new products, improving delivery system, creating eco-friendly anesthetics, and adopting new technologies for the diversification of the market.

Inhalation Anesthetics Market Companies:

• Baxter
• AbbVie
• Fresenius Kabi Canada Ltd.
• Halocarbon, LLC
• Piramal Critical Care
• Lunan Pharmaceutical Group
• Midmark Corporation
• NYSORA
• Sedana Medical AB
• VERO Biotech
• Troikaa
• Merck KGaA
• Dechra

View an Additional List of Companies in the Inhalation Anesthetics Market

• In July 2024, Sentara Health officials announced the reduction of climate pollution from a greenhouse gas used for anesthesia, part of the system’s wider effort was to reduce health care’s sizable carbon footprint. The health system’s hospitals throughout Virginia and North Carolina had largely phased out the anesthetic gas called desflurane, which was the most potent greenhouse gas among inhaled anesthetics.
• In October 2021, a team of scientists at the Max Planck Institute for Experimental Medicine in Göttingen had found that isoflurane, an inhaled anesthetic drug switched on an import pathway across the blood-brain barrier. Isoflurane supported chemotherapy of brain tumors in mice. This drug delivery system could be used to treat many diseases of the nervous system.

Analyst View:

The development of new anesthetic drug delivery systems, the rise in surgeries due to an increase in emergency situations, accidents, and chronic diseases, is propelling the market expansion globally. The market is also expected to grow due to the rising prevalence of chronic diseases, such as cancer, cardiovascular disease, and respiratory disease, along with government support for using inhalation anesthetics are all factors driving the growth of the inhalation anesthetics market.

More Related Reports

Predictive Maintenance Market
Aerospace Maintenance Chemicals Market
Maintenance, Repair, and Operations (MRO) Market
Virtual Hospitals Market
Inhalation Anesthesia Market